Nat Commun:乙二醇低聚物衍生的肌醇磷酸酯对血管钙化的抑制作用

2020-02-27 不详 网络

肌醇六磷酸酯(IP6)是一种天然产物,已知可抑制血管钙化(VC),但给药后效价有限且血浆暴露量低。本研究中,我们报告了一系列肌醇磷酸酯类似物作为结晶抑制剂的设计,其中4,6-二-O-(甲氧基-二甘醇)-肌醇-1,2,3,5-四(磷酸)(皮下注射后,OEG2)2-IP4与IP6相比,显示出更高的体外活性以及更有利的药代动力学和安全性。 (OEG2)2-IP4可有效稳定钙蛋白颗粒(CPP)的生长,在不

肌醇六磷酸酯(IP6)是一种天然产物,已知可抑制血管钙化(VC),但给药后效价有限且血浆暴露量低。

本研究中,我们报告了一系列肌醇磷酸酯类似物作为结晶抑制剂的设计,其中4,6-二-O-(甲氧基-二甘醇)-肌醇-1,2,3,5-四(磷酸)(皮下注射后,OEG2)2-IP4与IP6相比,显示出更高的体外活性以及更有利的药代动力学和安全性。 (OEG2)2-IP4可有效稳定钙蛋白颗粒(CPP)的生长,在不同的VC体外模型(即人血清,原代细胞培养物和组织外植体)中始终显示出低微摩尔活性,并在很大程度上消除了VC在啮齿动物模型中的发育,同时不会引起与血清钙螯合有关的毒性。

总之,该研究结果提示了一种独立于VC病因的作用机制,(OEG2)2-IP4破坏了病理性钙化的成核和生长。

原始出处:

Antonia E. Schantl, Anja Verhulst, et al., Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. Nat Commun. 2020; 11: 721. doi: 10.1038/s41467-019-14091-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884141, encodeId=297318841414b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue May 19 22:10:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087664, encodeId=5845208e66466, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed May 27 00:10:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755214, encodeId=9bb61e55214cc, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Mon Nov 16 07:10:00 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635464, encodeId=c2e916354646a, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Fri Nov 20 06:10:00 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-05-19 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884141, encodeId=297318841414b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue May 19 22:10:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087664, encodeId=5845208e66466, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed May 27 00:10:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755214, encodeId=9bb61e55214cc, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Mon Nov 16 07:10:00 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635464, encodeId=c2e916354646a, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Fri Nov 20 06:10:00 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-05-27 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884141, encodeId=297318841414b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue May 19 22:10:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087664, encodeId=5845208e66466, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed May 27 00:10:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755214, encodeId=9bb61e55214cc, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Mon Nov 16 07:10:00 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635464, encodeId=c2e916354646a, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Fri Nov 20 06:10:00 CST 2020, time=2020-11-20, status=1, ipAttribution=)]
    2020-11-16 weiz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884141, encodeId=297318841414b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue May 19 22:10:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087664, encodeId=5845208e66466, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed May 27 00:10:00 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755214, encodeId=9bb61e55214cc, content=<a href='/topic/show?id=536f2338e8d' target=_blank style='color:#2F92EE;'>#乙二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23387, encryptionId=536f2338e8d, topicName=乙二醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b11f36846752, createdName=weiz, createdTime=Mon Nov 16 07:10:00 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1635464, encodeId=c2e916354646a, content=<a href='/topic/show?id=b099549160a' target=_blank style='color:#2F92EE;'>#抑制作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54916, encryptionId=b099549160a, topicName=抑制作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd322475383, createdName=124987a0m73(暂无昵称), createdTime=Fri Nov 20 06:10:00 CST 2020, time=2020-11-20, status=1, ipAttribution=)]